These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21493741)

  • 1. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
    März W; Genser B; Drechsler C; Krane V; Grammer TB; Ritz E; Stojakovic T; Scharnagl H; Winkler K; Holme I; Holdaas H; Wanner C;
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1316-25. PubMed ID: 21493741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators.
    Wanner C; Krane V; Ruf G; März W; Ritz E
    Kidney Int Suppl; 1999 Jul; 71():S222-6. PubMed ID: 10412782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis.
    Krane V; Heinrich F; Meesmann M; Olschewski M; Lilienthal J; Angermann C; Störk S; Bauersachs J; Wanner C; Frantz S;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):394-400. PubMed ID: 19158371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.
    Kopecky C; Genser B; Drechsler C; Krane V; Kaltenecker CC; Hengstschläger M; März W; Wanner C; Säemann MD; Weichhart T
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):224-31. PubMed ID: 25424990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
    Hoffmann MM; März W; Genser B; Drechsler C; Wanner C
    Atherosclerosis; 2011 Dec; 219(2):659-62. PubMed ID: 21871624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E;
    N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
    Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.
    Chan KE; Thadhani R; Lazarus JM; Hakim RM
    Clin J Am Soc Nephrol; 2010 May; 5(5):856-66. PubMed ID: 20338963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
    Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
    Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study.
    Fung CSC; Wan EYF; Chan AKC; Lam CLK
    BMC Cardiovasc Disord; 2017 Jun; 17(1):166. PubMed ID: 28645252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J; Gosho M; Budinski D; Hounslow N
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
    Krane V; Berger M; Lilienthal J; Winkler K; Schambeck C; Wanner C;
    Clin J Am Soc Nephrol; 2010 May; 5(5):874-81. PubMed ID: 20185595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pitavastatin: clinical effects from the LIVES Study.
    Teramoto T
    Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of low dose atorvastatin in diabetic dyslipidaemia.
    Pola P; Kumar R; Reddy AP; Rajagopal G; Harinarayan CV; Suresh V; Suchitra MM; Sachan A
    J Indian Med Assoc; 2009 Nov; 107(11):807-9. PubMed ID: 20469785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.